Thanks for an Amazing
SynBioBeta 2025
Early Bird Tickets for SynBioBeta 2026 Are Live — Get Yours Now
May 4-7
2026
San Jose Convention Center
California, USA
May 4-7
2026
San Jose Convention Center
California, USA
May 4-7
2026
San Jose Convention Center
California, USA
Welcome to the Global Synthetic Biology Conference.
Welcome to the Global Synthetic Biology Conference.
Be part of a dynamic community of the world’s top innovators, thought leaders, entrepreneurs, and investors who are using synthetic biology to build a better world. From healthcare and agriculture to chemicals, materials, consumer goods, and biomanufacturing—discover how synbio is transforming entire industries.
Be part of a dynamic community of the world’s top innovators, thought leaders, entrepreneurs, and investors who are using synthetic biology to build a better world. From healthcare and agriculture to chemicals, materials, consumer goods, and biomanufacturing—discover how synbio is transforming entire industries.
This year, we’re shining a spotlight on one of the most exciting frontiers: the convergence of synthetic biology and AI. Explore how advanced computation is accelerating biological discovery and unlocking new possibilities. Don’t miss this opportunity to be at the forefront of innovation. Register now and join us for a transformative experience.
This year, we’re shining a spotlight on one of the most exciting frontiers: the convergence of synthetic biology and AI. Explore how advanced computation is accelerating biological discovery and unlocking new possibilities. Don’t miss this opportunity to be at the forefront of innovation. Register now and join us for a transformative experience.
Top Sessions You Can’t Miss
1
-
CEO Luncheon – Navigating Today’s Economic Challenges: Leading Through Uncertainty
This invite-only luncheon is a unique opportunity to connect with fellow biotech and deep tech CEO's facing today’s most pressing financial challenges. Hosted at SynBioBeta 2025, the gathering will foster candid peer discussion and high-level networking in an intimate setting. The session, Navigating Today’s Economic Challenges: Leading Through Uncertainty, will feature a conversation moderated by Alison Snyder from Axios, bringing together Hermann Hauser (Amadeus Capital) and David Choi (JPMorgan), who will share their perspectives on the current economic landscape, shifting investor expectations, and the strategies companies are adopting to stay resilient and competitive. Against a backdrop of market volatility, capital constraints, and global uncertainty, this conversation offers grounded insights and practical guidance for executives leading through turbulent times. https://lu.ma/4ppwczeh
[…]
2
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
3
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
4
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
5
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
6
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
7
-
Unbound Biology: Cracking the Age Code
What if aging were optional? In this provocative session, Bryan Johnson (Founder, Don't Die) and Jason Kelly (Co-Founder & CEO, Ginkgo Bioworks) explore how synthetic biology, data-driven optimization, and radical self-experimentation are converging to rewrite the rules of human longevity. From cellular reprogramming to biological automation, they’ll discuss what it takes to crack the age code—and what the future of ageless living might look like.
[…]
8
-
A Rallying Call to Work on Longevity
In this keynote, Peter Diamandis, will issue a rallying call to redefine how we think about aging and harness the synergy of biotech, AI, and bold thinking to push the boundaries of healthy lifespan extension. He will draw on insights from The Longevity Insider’s Guide to present transformative solutions poised to disrupt the healthcare landscape. He will spotlight how entrepreneurs, researchers, and investors can join forces to accelerate breakthroughs and overcome the most urgent challenges in aging. By shifting from scarcity to possibility, he will show how collective innovation can usher in an era of unprecedented longevity, redefining what it means to thrive at every stage of life.
[…]
9
-
From Startup to Scaleup: Insights to How P&G is Harnessing Bio Innovation for Superior Performance and Sustainability
P&G is a leading consumer products company led by consumer insights- they can tell you that today’s consumers want clean, healthy products in their homes to provide for their families' personal care needs. To meet these expectations, innovators are integrating new approaches to transform their supply chains, minimize waste streams, and drive environmentally sound solutions for a more sustainable planet. Join two senior leaders for a closer look at how synbio can positively impact consumer products and what specific challenges–both technical and societal–we need to solve to get there. Hear how corporate leaders evaluate new innovations and where they see unmet needs in the market. This session will highlight how corporates and startups can work together to achieve the functional and sustainable performance consumers demand.
[…]
10
-
Crossing the Chasm in FoodTech: From Innovation to Mainstream
In the fast-changing world of FoodTech, innovations like precision fermentation, plant-based alternatives, and biotechnologies have the potential to revolutionize the industry. However, challenges such as cultural acceptance, consumer skepticism, and economic scalability must be overcome for these innovations to achieve mainstream success. This session will explore the key factors required to bridge the gap from niche products to widespread adoption, including strategies for addressing consumer behavior, unit economics, and market scalability, paving the way for sustainable, scalable food solutions for the future.
[…]
1
-
CEO Luncheon – Navigating Today’s Economic Challenges: Leading Through Uncertainty
This invite-only luncheon is a unique opportunity to connect with fellow biotech and deep tech CEO's facing today’s most pressing financial challenges. Hosted at SynBioBeta 2025, the gathering will foster candid peer discussion and high-level networking in an intimate setting. The session, Navigating Today’s Economic Challenges: Leading Through Uncertainty, will feature a conversation moderated by Alison Snyder from Axios, bringing together Hermann Hauser (Amadeus Capital) and David Choi (JPMorgan), who will share their perspectives on the current economic landscape, shifting investor expectations, and the strategies companies are adopting to stay resilient and competitive. Against a backdrop of market volatility, capital constraints, and global uncertainty, this conversation offers grounded insights and practical guidance for executives leading through turbulent times. https://lu.ma/4ppwczeh
[…]
2
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
3
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
4
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
5
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
6
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
7
-
Unbound Biology: Cracking the Age Code
What if aging were optional? In this provocative session, Bryan Johnson (Founder, Don't Die) and Jason Kelly (Co-Founder & CEO, Ginkgo Bioworks) explore how synthetic biology, data-driven optimization, and radical self-experimentation are converging to rewrite the rules of human longevity. From cellular reprogramming to biological automation, they’ll discuss what it takes to crack the age code—and what the future of ageless living might look like.
[…]
8
-
A Rallying Call to Work on Longevity
In this keynote, Peter Diamandis, will issue a rallying call to redefine how we think about aging and harness the synergy of biotech, AI, and bold thinking to push the boundaries of healthy lifespan extension. He will draw on insights from The Longevity Insider’s Guide to present transformative solutions poised to disrupt the healthcare landscape. He will spotlight how entrepreneurs, researchers, and investors can join forces to accelerate breakthroughs and overcome the most urgent challenges in aging. By shifting from scarcity to possibility, he will show how collective innovation can usher in an era of unprecedented longevity, redefining what it means to thrive at every stage of life.
[…]
9
-
From Startup to Scaleup: Insights to How P&G is Harnessing Bio Innovation for Superior Performance and Sustainability
P&G is a leading consumer products company led by consumer insights- they can tell you that today’s consumers want clean, healthy products in their homes to provide for their families' personal care needs. To meet these expectations, innovators are integrating new approaches to transform their supply chains, minimize waste streams, and drive environmentally sound solutions for a more sustainable planet. Join two senior leaders for a closer look at how synbio can positively impact consumer products and what specific challenges–both technical and societal–we need to solve to get there. Hear how corporate leaders evaluate new innovations and where they see unmet needs in the market. This session will highlight how corporates and startups can work together to achieve the functional and sustainable performance consumers demand.
[…]
10
-
Crossing the Chasm in FoodTech: From Innovation to Mainstream
In the fast-changing world of FoodTech, innovations like precision fermentation, plant-based alternatives, and biotechnologies have the potential to revolutionize the industry. However, challenges such as cultural acceptance, consumer skepticism, and economic scalability must be overcome for these innovations to achieve mainstream success. This session will explore the key factors required to bridge the gap from niche products to widespread adoption, including strategies for addressing consumer behavior, unit economics, and market scalability, paving the way for sustainable, scalable food solutions for the future.
[…]
1
-
CEO Luncheon – Navigating Today’s Economic Challenges: Leading Through Uncertainty
This invite-only luncheon is a unique opportunity to connect with fellow biotech and deep tech CEO's facing today’s most pressing financial challenges. Hosted at SynBioBeta 2025, the gathering will foster candid peer discussion and high-level networking in an intimate setting. The session, Navigating Today’s Economic Challenges: Leading Through Uncertainty, will feature a conversation moderated by Alison Snyder from Axios, bringing together Hermann Hauser (Amadeus Capital) and David Choi (JPMorgan), who will share their perspectives on the current economic landscape, shifting investor expectations, and the strategies companies are adopting to stay resilient and competitive. Against a backdrop of market volatility, capital constraints, and global uncertainty, this conversation offers grounded insights and practical guidance for executives leading through turbulent times. https://lu.ma/4ppwczeh
[…]
2
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
3
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
4
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
5
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
6
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
7
-
Unbound Biology: Cracking the Age Code
What if aging were optional? In this provocative session, Bryan Johnson (Founder, Don't Die) and Jason Kelly (Co-Founder & CEO, Ginkgo Bioworks) explore how synthetic biology, data-driven optimization, and radical self-experimentation are converging to rewrite the rules of human longevity. From cellular reprogramming to biological automation, they’ll discuss what it takes to crack the age code—and what the future of ageless living might look like.
[…]
8
-
A Rallying Call to Work on Longevity
In this keynote, Peter Diamandis, will issue a rallying call to redefine how we think about aging and harness the synergy of biotech, AI, and bold thinking to push the boundaries of healthy lifespan extension. He will draw on insights from The Longevity Insider’s Guide to present transformative solutions poised to disrupt the healthcare landscape. He will spotlight how entrepreneurs, researchers, and investors can join forces to accelerate breakthroughs and overcome the most urgent challenges in aging. By shifting from scarcity to possibility, he will show how collective innovation can usher in an era of unprecedented longevity, redefining what it means to thrive at every stage of life.
[…]
9
-
From Startup to Scaleup: Insights to How P&G is Harnessing Bio Innovation for Superior Performance and Sustainability
P&G is a leading consumer products company led by consumer insights- they can tell you that today’s consumers want clean, healthy products in their homes to provide for their families' personal care needs. To meet these expectations, innovators are integrating new approaches to transform their supply chains, minimize waste streams, and drive environmentally sound solutions for a more sustainable planet. Join two senior leaders for a closer look at how synbio can positively impact consumer products and what specific challenges–both technical and societal–we need to solve to get there. Hear how corporate leaders evaluate new innovations and where they see unmet needs in the market. This session will highlight how corporates and startups can work together to achieve the functional and sustainable performance consumers demand.
[…]
10
-
Crossing the Chasm in FoodTech: From Innovation to Mainstream
In the fast-changing world of FoodTech, innovations like precision fermentation, plant-based alternatives, and biotechnologies have the potential to revolutionize the industry. However, challenges such as cultural acceptance, consumer skepticism, and economic scalability must be overcome for these innovations to achieve mainstream success. This session will explore the key factors required to bridge the gap from niche products to widespread adoption, including strategies for addressing consumer behavior, unit economics, and market scalability, paving the way for sustainable, scalable food solutions for the future.
[…]
What you'll learn
Explore the intersection of biological science, engineering, and entrepreneurship. Discover cutting-edge tools and technologies, gain insights from industry leaders, and develop the skills you need to launch and grow a synthetic biology venture.
Who you'll meet
Connect with trailblazers—bioengineers, biological scientists, investors, and innovators—who are reshaping the future of synthetic biology. Engage in conversations that drive the bio revolution forward.
What to expect
Immerse yourself in a vibrant entrepreneurial community full of passionate, supportive individuals. Expect a dynamic schedule packed with inspiring talks, hands-on demos, and endless opportunities for collaboration. You’ll leave with fresh ideas, new partnerships, and a clear vision for the future.
fortune 500 tech scouts including:
Over 100 sponsors & exhibitors:
Over 50 Investors attending including:
Pages
Other
Copyright SynBioBeta 2025
Pages
Other
Copyright SynBioBeta 2025
Pages
Other
Copyright SynBioBeta 2025
